PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 10, 2026RSC Advances0 citationsOpen Access

Structure-based design and optimization of cyclic peptide ligands targeting delta-like ligand 3

XGXinyan GaoXZXiaochuan ZhaWLWenhao Liu

Key Points

  • The aim is to design and optimize cyclic peptide ligands that specifically target DLL3.
  • Introduced a rigid cyclopropane mimic at a specific valine residue
  • Characterized the binding affinity using KD measurements
  • B5, a cyclic peptide ligand, showed high binding affinity for DLL3 with KD of 12.3 nM
  • This study identifies a promising DLL3-targeted theranostic scaffold

Abstract

Introducing a rigid cyclopropane mimic at a key valine residue yielded B5, a high-affinity cyclic peptide ( K D = 12.3 nM) targeting DLL3, providing a potential DLL3-targeted theranostic scaffold.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gao et al. (2026) studied this question.

synapsesocial.com/papers/6a0021b7c8f74e3340f9ca01https://doi.org/10.1039/d6ra02966c
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models2024 · 24 citations
  2. 21153P Preclinical characterization of MC339: A novel radiotherapeutic agent for DLL3 expressing cancers2024 · 2 citations
  3. 3DLL 3 regulates the migration and invasion of small cell lung cancer by modulating Snail2019 · 85 citations
  4. 4Peptide–Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics2024 · 97 citations
  5. 5ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update.2025 · 17 citations